How Macrolide's synthetic chemistry could make more effective macrolides
Macrolide Pharmaceuticals Inc. is using a synthetic chemistry platform to generate novel macrolide antibiotics with improved efficacy over macrolides derived from natural products. The company is focusing on Gram-negative pathogens.
The first macrolide antibiotic, erythromycin, was isolated from bacteria over 50 years ago. Successive macrolides have been derived from erythromycin and are widely used for Gram-positive infections.
But macrolides have limited efficacy in Gram-negative pathogens, and resistance to the class is growing. CEO Lawrence Miller said the reasons are